Associate Professor, Univ. Lille, CHU Lille, INSERM, Service de Chirurgie Maxillo-Faciale et Stomatologie, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France.
Resident, Univ. Lille, CHU Lille, INSERM, Service de Chirurgie Maxillo-Faciale et Stomatologie, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France.
J Oral Maxillofac Surg. 2021 Aug;79(8):1650-1671. doi: 10.1016/j.joms.2021.02.034. Epub 2021 Feb 27.
Development of minimally invasive therapies for temporomandibular joint osteoarthritis (TMJOA) has focused on drug intra-articular injections to avoid the systemic adverse effects experienced when these substances are administered orally. Therefore, we performed a systematic review to answer the question "Which method of induction of a TMJOA-related pain model in rats leads to prolonged painful symptoms, allowing the best assessment of a sustained drug delivery system?"
Following the PRISMA guidelines, we searched MEDLINE for papers published from 1994 to July 2020 on a TMJ arthritis model using rats. We identified the means of pain induction and of nociception assessment. We assessed protocol bias using an adaptation of the QUADAS-2 tool. Animal selection, the reference standard method of pain assessment, applicability of a statistical assessment, and flow and timing were assessed.
Of the 59 full papers we reviewed, 41 performed no pain assessment after the first 7 days following induction of the TMJ-related pain model. We eventually identified 18 long-term TMJOA-related pain models. Pain was induced by injection of toxic substances, most commonly Freund's complete adjuvant (50 μg per 50 μl), formalin at various concentrations, or monosodium iodoacetate (0,5 mg per 50 μl), into the TMJ, or by physical methods. Few studies reported data on pain after 21 days of follow-up. Heterogeneity of induction methods, pain assessment methods, and flow and timing biases precluded a meta-analysis.
Given that pain is 1 of the main symptoms of TMJOA, experimental study protocols should include long-term pain assessment.
为了避免将这些物质经口给药时出现的全身不良反应,针对颞下颌关节骨关节炎(TMJOA)的微创治疗方法主要集中于关节内药物注射。因此,我们进行了一项系统评价,旨在回答“哪种诱导 TMJOA 相关疼痛模型的方法会导致更持久的疼痛症状,从而能够更好地评估持续药物输送系统?”这一问题。
根据 PRISMA 指南,我们在 MEDLINE 中检索了自 1994 年至 2020 年 7 月期间发表的使用大鼠的 TMJ 关节炎模型的相关文献。我们确定了疼痛诱导和伤害感受评估的方法。我们使用 QUADAS-2 工具的改编版评估了方案偏倚。我们评估了动物选择、疼痛评估的参考标准方法、统计评估的适用性以及流程和时间安排。
在我们评价的 59 篇全文中,有 41 篇在诱导 TMJ 相关疼痛模型后的第 7 天内没有进行任何疼痛评估。我们最终确定了 18 种长期 TMJOA 相关疼痛模型。疼痛通过将有毒物质(最常见的是弗氏完全佐剂,50μg/50μl)、不同浓度的福尔马林或单碘乙酸(0.5mg/50μl)注射到 TMJ 中,或通过物理方法诱导。很少有研究报告了 21 天随访后的疼痛数据。由于诱导方法、疼痛评估方法以及流程和时间安排的异质性,无法进行荟萃分析。
鉴于疼痛是 TMJOA 的主要症状之一,实验研究方案应包括长期疼痛评估。